Search research articles
Contact Us
Filters
Showing results (91-100 of 107) with videos related to
Page
of 11
Sort By:
Naunyn-Schmiedeberg'S Archives of Pharmacology
|
January 22, 2025
The anti-dyskinetic effect of the clinic-ready mGluR<sub>2 </sub>positive allosteric modulator AZD8529 in the 6-OHDA-lesioned rat
Judy Shaqfah, Woojin Kang, Fleur Gaudette, et al.
Neuropharmacology
|
January 24, 2021
Combined 5-HT<sub>2A</sub> and mGlu<sub>2</sub> modulation for the treatment of dyskinesia and psychosis in Parkinson's disease
Cynthia Kwan, Imane Frouni, Stephen G Nuara, et al.
European Journal of Pharmacology
|
July 5, 2022
Effect of glycine transporter 1 inhibition with bitopertin on parkinsonism and L-DOPA induced dyskinesia in the 6-OHDA-lesioned rat
Imane Frouni, Woojin Kang, Dominique Bédard, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
October 23, 2010
Fatty acid amide hydrolase (FAAH) inhibition reduces L-3,4-dihydroxyphenylalanine-induced hyperactivity in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned non-human primate model of Parkinson's disease
Tom H Johnston, Philippe Huot, Susan H Fox, et al.
The European Journal of Neuroscience
|
January 17, 2020
The highly selective mGlu<sub>2</sub> receptor positive allosteric modulator LY-487,379 alleviates l-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease
Adjia Hamadjida, Lamia Sid-Otmane, Cynthia Kwan, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
March 19, 2025
Biomarkers of Histological Response in Lanifibranor-treated Patients With Metabolic Dysfunction-associated Steatohepatitis
Jérôme Boursier, Hugo Hervé, Marine Roux, et al.
Nature Communications
|
May 10, 2024
The pan-PPAR agonist lanifibranor improves cardiometabolic health in patients with metabolic dysfunction-associated steatohepatitis
Michael P Cooreman, Javed Butler, Robert P Giugliano, et al.
Neuropharmacology
|
June 18, 2013
TC-8831, a nicotinic acetylcholine receptor agonist, reduces L-DOPA-induced dyskinesia in the MPTP macaque
Tom H Johnston, Philippe Huot, Susan H Fox, et al.
Journal of Inherited Metabolic Disease
|
December 15, 2021
Oral treatment for mucopolysaccharidosis VI: Outcomes of the first phase IIa study with odiparcil
Nathalie Guffon, Pratima Chowdary, Elisa Leão Teles, et al.
Journal of Hepatology
|
January 17, 2025
Pan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD
Diana Barb, Srilaxmi Kalavalapalli, Eddison Godinez Leiva, et al.
Page
of 11
Search research articles
Search
Showing results (91-100 of 107) with videos related to
Sort By:
Page
of 11
Naunyn-Schmiedeberg'S Archives of Pharmacology
|
January 22, 2025
The anti-dyskinetic effect of the clinic-ready mGluR<sub>2 </sub>positive allosteric modulator AZD8529 in the 6-OHDA-lesioned rat
Judy Shaqfah, Woojin Kang, Fleur Gaudette, et al.
Neuropharmacology
|
January 24, 2021
Combined 5-HT<sub>2A</sub> and mGlu<sub>2</sub> modulation for the treatment of dyskinesia and psychosis in Parkinson's disease
Cynthia Kwan, Imane Frouni, Stephen G Nuara, et al.
European Journal of Pharmacology
|
July 5, 2022
Effect of glycine transporter 1 inhibition with bitopertin on parkinsonism and L-DOPA induced dyskinesia in the 6-OHDA-lesioned rat
Imane Frouni, Woojin Kang, Dominique Bédard, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
October 23, 2010
Fatty acid amide hydrolase (FAAH) inhibition reduces L-3,4-dihydroxyphenylalanine-induced hyperactivity in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned non-human primate model of Parkinson's disease
Tom H Johnston, Philippe Huot, Susan H Fox, et al.
The European Journal of Neuroscience
|
January 17, 2020
The highly selective mGlu<sub>2</sub> receptor positive allosteric modulator LY-487,379 alleviates l-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease
Adjia Hamadjida, Lamia Sid-Otmane, Cynthia Kwan, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
March 19, 2025
Biomarkers of Histological Response in Lanifibranor-treated Patients With Metabolic Dysfunction-associated Steatohepatitis
Jérôme Boursier, Hugo Hervé, Marine Roux, et al.
Nature Communications
|
May 10, 2024
The pan-PPAR agonist lanifibranor improves cardiometabolic health in patients with metabolic dysfunction-associated steatohepatitis
Michael P Cooreman, Javed Butler, Robert P Giugliano, et al.
Neuropharmacology
|
June 18, 2013
TC-8831, a nicotinic acetylcholine receptor agonist, reduces L-DOPA-induced dyskinesia in the MPTP macaque
Tom H Johnston, Philippe Huot, Susan H Fox, et al.
Journal of Inherited Metabolic Disease
|
December 15, 2021
Oral treatment for mucopolysaccharidosis VI: Outcomes of the first phase IIa study with odiparcil
Nathalie Guffon, Pratima Chowdary, Elisa Leão Teles, et al.
Journal of Hepatology
|
January 17, 2025
Pan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD
Diana Barb, Srilaxmi Kalavalapalli, Eddison Godinez Leiva, et al.
Page
of 11